Switching From Semaglutide to Tirzepatide: What Happens in the Four Months

Last reviewed 17 August 2026 · Educational, not medical advice · Dose changes are a decision for your prescriber · No sponsorships, no affiliate links

Which product you land on depends on which one you are leaving

"Semaglutide to tirzepatide" describes a molecule change that shows up as several different brand changes, and the paperwork differs more than the pharmacology does.

The indication swap in the obesity lane is the one people miss. Moving from Wegovy to Zepbound gains you the only drug approval of any class for moderate-to-severe obstructive sleep apnea, and gives up both the cardiovascular risk-reduction indication earned in SELECT and the MASH indication granted in August 2025. If you have heart or liver disease, that trade may not be worth six percentage points of weight.

Why there is no conversion chart worth trusting

Neither Novo Nordisk nor Eli Lilly publishes a cross-product conversion, and the FDA has never issued one. These are separate approvals, not interchangeable products. The charts circulating online are practice patterns somebody wrote down, and they are presented with more confidence than the underlying evidence supports.

The reason a conversion cannot exist is mechanistic. Semaglutide activates GLP-1. Tirzepatide activates GIP as well. Two drugs acting through different receptor combinations do not have parallel dose-response curves, so a ratio that held at one point on the ladder would not hold at the next. There is no exchange rate because there is no common unit.

What prescribers do instead is start tirzepatide at the bottom of its ladder and titrate on response. Being already adapted to a GLP-1 drug generally makes that climb easier than a first-ever start, but it does not let you skip steps. One pattern reported from practice is worth carrying into the conversation: people stable at the top of the semaglutide ladder often settle at tirzepatide 10 to 12.5 mg rather than needing 15 mg. The top dose is a ceiling, not a target.

What the four months actually look like

The single most useful thing to know in advance is that the middle of this process feels like failure and is not. You come off a drug at its full working dose and start another at its lowest. Appetite suppression drops before it rises. A stall, or a small regain, across weeks two through ten is the expected shape of the curve, and people abandon the switch there for no good reason.

The second most useful thing: do not leave a gap. If insurance or supply forces a delay, weeks with no drug at all cost more than a careful transition does.

If you are coming off compounded semaglutide

This deserves its own warning, because the usual advice does not transfer cleanly.

Compounded vials come in concentrations and units that branded pens do not use, and the actual delivered dose depends on the compounder, the reconstitution, and the draw. Your previous dose is therefore not a reliable anchor for anything, and telling a prescriber "I was on 2 mg" carries less information than it appears to. Treat a move to branded tirzepatide as a fresh start with a fresh titration.

The regulatory ground has also shifted. The FDA issued more than 55 warning letters to online sellers in September 2025 and 30 more to telehealth companies in March 2026, and on 30 April 2026 proposed permanently removing semaglutide, tirzepatide, and liraglutide from the 503B Bulks List - the change that would close the last broad legal pathway for compounded supply. Patient-specific 503A compounding with documented clinical need survives. If you are on compounded product, the supply question is worth settling before the dosing one.

What the switch will not fix

Roughly half of people who start a GLP-1 drug stop within a year. The propensity-matched cohort that found tirzepatide outperforming semaglutide in practice also found 55.9% of tirzepatide patients and 52.5% of semaglutide patients had discontinued by twelve months. A Danish national cohort of 77,310 adults found 52% stopped inside a year.

If your problem is cost, tolerability, or the sheer grind of an indefinite prescription, switching molecules does not address any of those - and the drug you switch to is the more expensive one. Tirzepatide is better value per point of weight lost, at $390 against $459, but it is a larger monthly bill. Solve the reason you might quit before you optimise the molecule.

The log is what stops you quitting in week six

Read the timeline above again and notice where the risk sits. It is not in the pharmacology, which is well understood, or in the destination, which the head-to-head data supports. It is in weeks two through ten, when you are on a fraction of a working dose, the scale has stalled or ticked upward, and the drug you left behind was working fine. That stretch feels exactly like a mistake and is not one.

Data is what gets you through it, and it has to be collected in advance to be worth anything. Log four weeks of weekly weights before the last semaglutide dose so you have a real baseline, then keep logging weekly through re-titration. When the plateau arrives, you will be looking at a curve with a known shape rather than at a number that seems to be going the wrong way. The difference between those two experiences is whether you are still on the drug in month five.

Zenday App is our top-ranked GLP-1 companion at 4.55/5, and the reason it fits this particular job is continuity: it works from first injection through maintenance and keeps doses, food, and side-effect days in one place, so the old drug and the new one sit in the same log instead of two that cannot be compared. It also treats side-effect management as a core pillar, which matters when you are about to re-run four escalations you thought you were finished with.

If you are coming off compounded product, the tracking problem is harder, because your previous dose is not a reliable reference point and a branded pen ladder will not describe what you were actually taking. Both of our top picks take custom doses rather than only the standard steps, so the log survives the move: Zenday keeps the compounded weeks and the branded weeks in the same continuous history, which is what makes a before-and-after comparison possible at all. Regimen goes deeper on the modelling, covering over 150 compounds in branded and compounded form with real-time pharmacokinetic curves and built-in reconstitution math. Full scoring for both is in our GLP-1 app ranking.

What the evidence does not show

• No trial has studied switching. Everything practical here comes from pharmacology, the head-to-head efficacy data, and reported prescribing practice.
• No validated dose equivalence exists, and the receptor difference makes one unlikely.
• Nothing quantifies the transition plateau. Its existence follows from the titration schedule; its size has not been measured.
• No head-to-head against Wegovy HD 7.2 mg, which reached 20.7% in its own trial. If your reason for switching is efficacy alone, that dose is worth asking about first.

Before you switch, ask your prescriber

• Have I actually reached the top of the semaglutide ladder, including Wegovy HD 7.2 mg?
• Do I have a cardiovascular, liver, or kidney indication that argues for staying?
• If I take insulin or a sulfonylurea, how are those doses changing?
• What target tirzepatide dose are we aiming for, and how will we know we are there?
• How do we avoid a supply gap while coverage changes?

Method and sources

Efficacy figures come from SURMOUNT-5, SURPASS-2, STEP UP, and SELECT as published, plus the JAMA Internal Medicine propensity-matched cohort and national persistence studies for real-world figures. There is no trial of switching between these products; statements about practice reflect reported prescribing patterns and are not a protocol. Prices are US manufacturer self-pay rates read on 17 August 2026. We take no money from any manufacturer and run no affiliate links. See also semaglutide vs tirzepatide, Ozempic to Mounjaro, and Zepbound to Wegovy for the reverse direction.